Antitumor activity and safety of combination therapy with the Toll-like receptor 9 agonist IMO-2055, erlotinib, and bevacizumab in advanced or metastatic non-small cell lung cancer patients who have progressed following chemotherapy
Titel:
Antitumor activity and safety of combination therapy with the Toll-like receptor 9 agonist IMO-2055, erlotinib, and bevacizumab in advanced or metastatic non-small cell lung cancer patients who have progressed following chemotherapy
Auteur:
Smith, David A. Conkling, Paul Richards, Donald A. Nemunaitis, John J. Boyd, Thomas E. Mita, Alain C. Bourdonnaye, Guillaume de La Wages, David Bexon, Alice S.